Serous Tubal Intraepithelial Carcinoma: A Concise Review for the Practicing Pathologist and Clinician
Ovarian cancer is the deadliest gynecologic malignancy, accounting for more than 14,000 deaths each year. With no established way to prevent or screen for it, the vast majority of cases are diagnosed as International Federation of Gynecology and Obstetrics (FIGO) stage III or higher. Individuals wit...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-02-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/10/2/102 |
| _version_ | 1798040509274390528 |
|---|---|
| author | S. Emily Bachert Anthony McDowell Dava Piecoro Lauren Baldwin Branch |
| author_facet | S. Emily Bachert Anthony McDowell Dava Piecoro Lauren Baldwin Branch |
| author_sort | S. Emily Bachert |
| collection | DOAJ |
| description | Ovarian cancer is the deadliest gynecologic malignancy, accounting for more than 14,000 deaths each year. With no established way to prevent or screen for it, the vast majority of cases are diagnosed as International Federation of Gynecology and Obstetrics (FIGO) stage III or higher. Individuals with germline <i>BRCA</i> mutations are at particularly high risk for epithelial ovarian cancer and have been the subject of many risk-reducing strategies. In the past ten years, studies looking at risk-reducing salpingo-oophorectomy (RRSO) in this population have uncovered an interesting association: up to 8% of women with <i>BRCA1</i> or <i>BRCA2</i> mutations who underwent RRSO had an associated serous tubal intraepithelial carcinoma (STIC). The importance of this finding is highlighted by the fact that up to 60% of ovarian cancer patients will also have an associated STIC. These studies have led to a paradigm shift that a subset of epithelial ovarian cancer originates not in the ovarian epithelium, but rather in the distal fallopian tube. In response to this, many providers have changed their practice by expanding the role of routine salpingectomy, hysterectomy, and sterilization procedures. The American College of Obstetricians and Gynecologists (ACOG) has acknowledged opportunistic salpingectomy as a safe strategy to reduce the risk of epithelial ovarian cancer in Committee Opinion #774. It is thus important for pathologists and clinicians to understand the definition of STIC; how it is diagnosed; and, most importantly, its clinical significance. |
| first_indexed | 2024-04-11T22:08:36Z |
| format | Article |
| id | doaj.art-0c67a874769543fab4b6548cd003c066 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-04-11T22:08:36Z |
| publishDate | 2020-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-0c67a874769543fab4b6548cd003c0662022-12-22T04:00:37ZengMDPI AGDiagnostics2075-44182020-02-0110210210.3390/diagnostics10020102diagnostics10020102Serous Tubal Intraepithelial Carcinoma: A Concise Review for the Practicing Pathologist and ClinicianS. Emily Bachert0Anthony McDowell1Dava Piecoro2Lauren Baldwin Branch3Department of Pathology and Laboratory Medicine, University of Kentucky College of Medicine, Lexington, KY 40536, USADepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Kentucky College of Medicine, Lexington, KY 40536, USADepartment of Pathology and Laboratory Medicine, University of Kentucky College of Medicine, Lexington, KY 40536, USADepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Kentucky College of Medicine, Lexington, KY 40536, USAOvarian cancer is the deadliest gynecologic malignancy, accounting for more than 14,000 deaths each year. With no established way to prevent or screen for it, the vast majority of cases are diagnosed as International Federation of Gynecology and Obstetrics (FIGO) stage III or higher. Individuals with germline <i>BRCA</i> mutations are at particularly high risk for epithelial ovarian cancer and have been the subject of many risk-reducing strategies. In the past ten years, studies looking at risk-reducing salpingo-oophorectomy (RRSO) in this population have uncovered an interesting association: up to 8% of women with <i>BRCA1</i> or <i>BRCA2</i> mutations who underwent RRSO had an associated serous tubal intraepithelial carcinoma (STIC). The importance of this finding is highlighted by the fact that up to 60% of ovarian cancer patients will also have an associated STIC. These studies have led to a paradigm shift that a subset of epithelial ovarian cancer originates not in the ovarian epithelium, but rather in the distal fallopian tube. In response to this, many providers have changed their practice by expanding the role of routine salpingectomy, hysterectomy, and sterilization procedures. The American College of Obstetricians and Gynecologists (ACOG) has acknowledged opportunistic salpingectomy as a safe strategy to reduce the risk of epithelial ovarian cancer in Committee Opinion #774. It is thus important for pathologists and clinicians to understand the definition of STIC; how it is diagnosed; and, most importantly, its clinical significance.https://www.mdpi.com/2075-4418/10/2/102sticepithelial ovarian cancerbrca mutation |
| spellingShingle | S. Emily Bachert Anthony McDowell Dava Piecoro Lauren Baldwin Branch Serous Tubal Intraepithelial Carcinoma: A Concise Review for the Practicing Pathologist and Clinician Diagnostics stic epithelial ovarian cancer brca mutation |
| title | Serous Tubal Intraepithelial Carcinoma: A Concise Review for the Practicing Pathologist and Clinician |
| title_full | Serous Tubal Intraepithelial Carcinoma: A Concise Review for the Practicing Pathologist and Clinician |
| title_fullStr | Serous Tubal Intraepithelial Carcinoma: A Concise Review for the Practicing Pathologist and Clinician |
| title_full_unstemmed | Serous Tubal Intraepithelial Carcinoma: A Concise Review for the Practicing Pathologist and Clinician |
| title_short | Serous Tubal Intraepithelial Carcinoma: A Concise Review for the Practicing Pathologist and Clinician |
| title_sort | serous tubal intraepithelial carcinoma a concise review for the practicing pathologist and clinician |
| topic | stic epithelial ovarian cancer brca mutation |
| url | https://www.mdpi.com/2075-4418/10/2/102 |
| work_keys_str_mv | AT semilybachert seroustubalintraepithelialcarcinomaaconcisereviewforthepracticingpathologistandclinician AT anthonymcdowell seroustubalintraepithelialcarcinomaaconcisereviewforthepracticingpathologistandclinician AT davapiecoro seroustubalintraepithelialcarcinomaaconcisereviewforthepracticingpathologistandclinician AT laurenbaldwinbranch seroustubalintraepithelialcarcinomaaconcisereviewforthepracticingpathologistandclinician |